Innovent's IBI354-Pertuzumab Combination Shows 95% Response Rate in Phase 2 Breast Cancer Trial

• Innovent Biologics presented Phase 2 results for IBI354 with pertuzumab in first-line HER2-positive advanced breast cancer on Oct. 25, 2026.
• Among 20 patients, the confirmed objective response rate reached 95%; the disease control rate was 100%.
• Survival data remained immature, with one progression-free survival event and no deaths at a median progression-free survival follow-up of 8.3 months.
• Grade 3 or higher treatment-related adverse events affected 20% of patients; no interstitial lung disease occurred.
• Phase 3 trials have begun in ovarian cancer and first-line HER2-positive advanced breast cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610250200PR_NEWS_USPR_____CN80332) on October 25, 2026, and is solely responsible for the information contained therein.